Literature DB >> 9543140

Expression and secretion of inhibin and activin in normal and neoplastic uterine tissues. High levels of serum activin A in women with endometrial and cervical carcinoma.

F Petraglia1, P Florio, S Luisi, R Gallo, A Gadducci, P Viganò, A M Di Blasio, A R Genazzani, W Vale.   

Abstract

Inhibins and activins are growth factors belonging to the transforming growth factor-beta) family and are known to influence cell proliferation and differentiation. Because transforming growth factor-beta is involved in physiological and tumoral changes of uterine tissues, the present study aimed to evaluate whether human normal and neoplastic endometrial and cervical epithelial cells express and secrete inhibin A, inhibin B, and activin A. To test this hypothesis, different approaches were used. By RT-PCR, the expression of specific messenger RNAs (mRNAs) for the inhibin alpha, activin betaA and betaB subunits, and activin receptor type II and type IIB was investigated: 1) in primary cultures of endometrial (stroma and epithelium) or cervical (epithelium) cells from healthy women; and 2) in specimens of endometrial or cervical carcinoma. To demonstrate a possible secretion of the proteins, dimeric inhibin A, inhibin B, and activin A were measured in culture medium of normal epithelial or stromal endometrial cells and in uterine washing fluid of healthy women or patients with endometrial adenocarcinoma. Levels of the proteins were also measured in serum of women with endometrial or cervical carcinoma. Cultured endometrial stromal or epithelial cells and epithelial cervical cells expressed inhibin alpha, activin betaA and betaB, and activin receptor type II and type IIB mRNAs. The same finding was obtained in specimens of endometrial or cervical carcinomas. Dimeric inhibin A, inhibin B, and activin A were measured in culture medium of both endometrial and cervical cells. In particular, resulting activin A levels were significantly higher in epithelial than in stromal cultured endometrial cells (P < 0.01). Dimeric proteins were also detected in the washing fluid of the uterine cavities of healthy women (controls) and with endometrial adenocarcinoma, in which higher activin A levels were found (P < 0.01 vs. controls). Women with endometrial carcinoma showed serum activin A levels significantly higher than healthy controls (P < 0.01), which significantly decreased after surgical removal of endometrial or cervical tumors (P < 0.01). The present study, for the first time, showed that inhibin A, inhibin B, and activin A, as well as activin receptors, are expressed in normal and neoplastic human uterine tissues. A secretion of activin A from tumoral cells into systemic circulation is suggested by the observation that the high levels in serum of patients with endometrial or cervical carcinoma decreased after the surgical removal of the tumor.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9543140     DOI: 10.1210/jcem.83.4.4689

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

1.  Upregulated INHBA expression may promote cell proliferation and is associated with poor survival in lung adenocarcinoma.

Authors:  Christopher W Seder; Wibisono Hartojo; Lin Lin; Amy L Silvers; Zhuwen Wang; Dafydd G Thomas; Thomas J Giordano; Guoan Chen; Andrew C Chang; Mark B Orringer; David G Beer
Journal:  Neoplasia       Date:  2009-04       Impact factor: 5.715

Review 2.  Molecular mechanism of sarcopenia and cachexia: recent research advances.

Authors:  Kunihiro Sakuma; Wataru Aoi; Akihiko Yamaguchi
Journal:  Pflugers Arch       Date:  2017-01-19       Impact factor: 3.657

3.  Overexpression of activin A in stage IV colorectal cancer.

Authors:  S Wildi; J Kleeff; H Maruyama; C A Maurer; M W Büchler; M Korc
Journal:  Gut       Date:  2001-09       Impact factor: 23.059

4.  Inhibin/activin subunits alpha, beta-A and beta-B are differentially expressed in normal human endometrium throughout the menstrual cycle.

Authors:  Ioannis Mylonas; Udo Jeschke; Irmgard Wiest; Anna Hoeing; Julia Vogl; Naim Shabani; Christina Kuhn; Sandra Schulze; Markus S Kupka; Klaus Friese
Journal:  Histochem Cell Biol       Date:  2004-10-12       Impact factor: 4.304

5.  Activin receptor signaling regulates prostatic epithelial cell adhesion and viability.

Authors:  Derek P Simon; Sivan Vadakkadath Meethal; Andrea C Wilson; Miguel J Gallego; Stephanie L Weinecke; Erin Bruce; Patrick F Lyons; Ryan J Haasl; Richard L Bowen; Craig S Atwood
Journal:  Neoplasia       Date:  2009-04       Impact factor: 5.715

6.  Inhibin/activin-betaE subunit in normal and malignant human cervical tissue and cervical cancer cell lines.

Authors:  Florian Bergauer; Ansgar Brüning; Naim Shabani; Thomas Blankenstein; Julia Jückstock; Darius Dian; Ioannis Mylonas
Journal:  J Mol Histol       Date:  2009-12-24       Impact factor: 2.611

7.  Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass.

Authors:  Kunihiro Sakuma; Akihiko Yamaguchi
Journal:  J Cachexia Sarcopenia Muscle       Date:  2012-01-12       Impact factor: 12.910

8.  Evidence of inhibin/activin subunit betaC and betaE synthesis in normal human endometrial tissue.

Authors:  Ioannis Mylonas; Ansgar Brüning; Naim Shabani; Susanne Kunze; Markus S Kupka
Journal:  Reprod Biol Endocrinol       Date:  2010-11-19       Impact factor: 5.211

9.  Uterine epithelial cell regulation of DC-SIGN expression inhibits transmitted/founder HIV-1 trans infection by immature dendritic cells.

Authors:  Daniel O Ochiel; Christina Ochsenbauer; John C Kappes; Mimi Ghosh; John V Fahey; Charles R Wira
Journal:  PLoS One       Date:  2010-12-14       Impact factor: 3.240

10.  High circulating activin A level is associated with tumor progression and predicts poor prognosis in lung adenocarcinoma.

Authors:  Mir Alireza Hoda; Anita Rozsas; Elisabeth Lang; Thomas Klikovits; Zoltan Lohinai; Szilvia Torok; Judit Berta; Matyas Bendek; Walter Berger; Balazs Hegedus; Walter Klepetko; Ferenc Renyi-Vamos; Michael Grusch; Balazs Dome; Viktoria Laszlo
Journal:  Oncotarget       Date:  2016-03-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.